These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 8117373

  • 1. [A sickle cell homozygote with transfusion deadlock. Favorable outcome with hydroxyurea treatment].
    Monsaingeon-Lion A, Le Pennec PY, Bridey F, Girard M, Ricard R, Gross E, Tchernia G.
    Rev Fr Transfus Hemobiol; 1993 Dec; 36(6):477-84. PubMed ID: 8117373
    [Abstract] [Full Text] [Related]

  • 2. Red blood cell alloimmunization in sickle cell disease patients in Uganda.
    Natukunda B, Schonewille H, Ndugwa C, Brand A.
    Transfusion; 2010 Jan; 50(1):20-5. PubMed ID: 19821949
    [Abstract] [Full Text] [Related]

  • 3. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions.
    Aygun B, Padmanabhan S, Paley C, Chandrasekaran V.
    Transfusion; 2002 Jan; 42(1):37-43. PubMed ID: 11896310
    [Abstract] [Full Text] [Related]

  • 4. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [Abstract] [Full Text] [Related]

  • 5. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood.
    Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B.
    N Engl J Med; 1990 Jun 07; 322(23):1617-21. PubMed ID: 2342522
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Transfusion and alloimmunization in sickle cell anemia patients].
    Norol F, Nadjahi J, Bachir D, Desaint C, Guillou Bataille M, Beaujean F, Bierling P, Bonin P, Galacteros F, Duedari N.
    Transfus Clin Biol; 1994 Jun 07; 1(1):27-34. PubMed ID: 8186850
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia.
    Keikhaei B, Yousefi H, Bahadoram M.
    Glob J Health Sci; 2015 Aug 19; 8(3):252-6. PubMed ID: 26493428
    [Abstract] [Full Text] [Related]

  • 11. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
    Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, Jordan L, Lanzkron SM, Lottenberg R, Savage WJ, Tanabe PJ, Ware RE, Murad MH, Goldsmith JC, Ortiz E, Fulwood R, Horton A, John-Sowah J.
    JAMA; 2014 Sep 10; 312(10):1033-48. PubMed ID: 25203083
    [Abstract] [Full Text] [Related]

  • 12. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
    Jain DL, Sarathi V, Desai S, Bhatnagar M, Lodha A.
    Hemoglobin; 2012 Sep 10; 36(4):323-32. PubMed ID: 22734586
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Sickle cell anemia and transfusion safety in Bamako, Mali. Seroprevalence of HIV, HBV and HCV infections and alloimmunization belonged to Rh and Kell systems in sickle cell anemia patients].
    Diarra AB, Guindo A, Kouriba B, Dorie A, Diabaté DT, Diawara SI, Fané B, Touré BA, Traoré A, Gulbis B, Diallo DA.
    Transfus Clin Biol; 2013 Dec 10; 20(5-6):476-81. PubMed ID: 23916574
    [Abstract] [Full Text] [Related]

  • 16. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
    Italia K, Jain D, Gattani S, Jijina F, Nadkarni A, Sawant P, Nair S, Mohanty D, Ghosh K, Colah R.
    Blood Cells Mol Dis; 2009 Dec 10; 42(1):25-31. PubMed ID: 18954999
    [Abstract] [Full Text] [Related]

  • 17. Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease.
    Fasano RM, Booth GS, Miles M, Du L, Koyama T, Meier ER, Luban NL.
    Br J Haematol; 2015 Jan 10; 168(2):291-300. PubMed ID: 25256676
    [Abstract] [Full Text] [Related]

  • 18. Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease.
    Cox JV, Steane E, Cunningham G, Frenkel EP.
    Arch Intern Med; 1988 Nov 10; 148(11):2485-9. PubMed ID: 3142382
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR.
    N Engl J Med; 1995 May 18; 332(20):1317-22. PubMed ID: 7715639
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.